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Introduction
The ﬁrst recommendations for the diagnosis and treatment
of endometrial cancer had been published by the Uterus
Commission of the Gynecological Oncology Working
Group (AGO), afﬁliated to the German Society for Gyne-
cology and Obstetrics (DGGG) and the German Cancer
Society (DKG), in 1999 (S1 guideline). This guideline was
updated twice, on the S1-level, most recently in 2006.
Between October 2007 and 2008 another update was per-
formed on the S2k level by an interdisciplinary group of
experts representative of the users. The methodologic
procedure was based on the regulations described in the
DKG’s working instructions for producing interdisciplin-
ary consensus-based guidelines.
The process of developing consensus-based guidelines
(S2 konsensus guidelines) does not provide the systematic
preparation of the evidence; instead, a discussion and
critical evaluation of the published literature are carried
out by the members of the guideline group. During a
consensus conference, the participants also have an
opportunity to make suggestions for ways of expressing
the detailed guideline text in more concrete ways and
supplementing it. The basic principles and criteria for the
grading of the recommendations are discussed at the start
of the consensus procedure. Changes and additions to the
guideline on the basis of the voting results during the
nominal group process are carried out by the guideline
coordinators. The revised version is sent in written form
to all the members of the guideline group for ﬁnal com-
ments and adoption.
Epidemiology and risk factors
Endometrial cancer is the fourth most frequent cancer
among women in Germany. EC is the ninth most frequent
cause of cancer death. Type I EC (typically endometrioid
EC) is related to exposition to unopposed estrogens. For the
more aggressive type II EC (typically serous EC, clear cell
EC) only old age and preceding radiotherapy of the uterus
have been identiﬁed as risk factors.
Early detection and screening
Statements
r General screening cannot be recommended
r There is no evidence that the mortality can be reduced as a result of
screening in high-risk populations
Screening with endovaginal ultrasonography and sub-
sequent endometrial biopsy may be useful in high-risk
groups (obesity, diabetes mellitus, known endometrial
hyperplasia, hereditary nonpolyposis colorectal cancer
syndrome). Even in these women, however, there is a lack
of studies to demonstrate the efﬁcacy of screening. In
HNPCC syndrome, prophylactic hysterectomy (?bilateral
salpingoophorectomy) may be useful for prevention of EC
(?ovarian cancer).
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Statements
r It is necessary to obtain a histological sample in order to conﬁrm
the diagnosis
r There are no imaging techniques capable of replacing surgical
staging in endometrial carcinoma. In patients who are inoperable
due to comorbidities, magnetic resonance imaging may be helpful
for treatment planning
Postmenopausal bleeding and all abnormal bleeding
patterns in premenopausal patients with one of the risk
factors mentioned above should be examined as follows:
• gynecological examination.
• Transvaginal ultrasonography (suspicious, if endome-
trial thickness of more than 5 mm in postmenopausal
women with bleeding). In postmenopausal women on
hormone or SERM therapy and in premenopausal
patients measurement of the endometrial thickness
alone is not diagnostically useful.
• Hysteroscopy and fractionated curettage.
Clinical/histopathological diagnosis
Statements
r The histological classiﬁcation of endometrial carcinomas and their
precursor lesions is carried out in accordance with the WHO
requirements
r Minimum requirements for reporting histopathological ﬁndings in
endometrial carcinoma are: tumor type, grading, depth of invasion
into the Myometrium, cervical inﬁltration, lymph-node
involvement, R classiﬁcation, and vascular and lymphatic
invasion
The ‘‘term’’ adenomatous hyperplasia grades I–III
should not longer be used.
As both, serous and clear cell EC are associated with a
poor prognosis, even at low tumor stages, this diagnosis
must be explicitly mentioned, even if there is only focal
evidence of it in a type I carcinoma or in an endometrial
polyp.
It is only when there is certain evidence of inﬁltration of
the EC into the endocervical glands or endocervical stroma
that curettage is capable of leading to a diagnosis of stage
T2a or T2b.
The value of intraoperative macroscopic assessment
and/or frozen-section of the hysterectomy specimen is
uncertain to deﬁne the depth of myometrial invasion.
Structures for providing care
Care for patients with preinvasive lesions or EC should be
provided in collaboration between registered gynecologists
in private practice and specialized centers for gynecologi-
cal oncology, that work in accordance with the certiﬁcation
criteria of the AGO, the German Society of Gynecology
and Obstetrics (DGGG) and the German Cancer Society
(DKG).
Patient information
Statements
r Information materials (print or Internet media) that are of high
quality and produced with appropriate specialist competence
should be provided, in accordance with the quality requirements set
out in the Guideline on Gynecological Information. By
communicating the risks in a comprehensible way (including
details of incidences, rather than relative percentages), these
materials should provide patients with support in taking
independent decisions for or against medical procedures
r Information should be communicated to the patient both
comprehensively and accurately, observing the following basic
principles of patient-centered communication
(1) Expression of empathy and active listening
(2) Direct and sensitive ways of touching on difﬁcult subjects
(3) If possible, avoidance of specialized medical terms, or with
explanations of specialist terms being given if necessary
(4) Strategies for improving understanding (repetition, summing up
of important information, use of graphics, etc.)
(5) Encouraging the patient to ask questions
(6) Permission and encouragement to express emotions
(7) Offering further assistance (e.g., from self-help groups, psycho-
oncology, psychological cancer counseling)
Basic principles of treatment for primary EC
Decision making regarding the appropriate treatment is
carried out in an interdisciplinary tumor board involving
gynecological oncology, radiotherapy, anesthesiology,
pathology and the patient.
Only if there are contraindications for surgical treat-
ment, primary radiotherapy and/or systemic treatment
become an option.
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Statements
r Hyperplasia of the endometrium without atypia can be treated
conservatively
r Hyperplasia of the Endometrium with atypia is associated with a
high risk of malignant change. Conservative treatment should only
be attempted if the patient wishes to have a child and a high degree
of compliance can be expected
In patients with atypical endometrial hyperplasia there is
a risk of 30% of progression to invasive EC and a risk of
20–40% of invasive EC in the hysterectomy specimen that
has been missed by curettage. This risk has to be carefully
balanced against the wish for fertility preservation.
Conservative treatment for early EC
Statement
r Conservative therapy can be considered for women with well-
differentiated, progesterone receptor-positive endometrioid
endometrial carcinoma in clinical stage 1a who strongly wish to
have a child
Due to the high risk of recurrence after conservative
treatment, surgical therapy appropriate to the stage is
required if the patient’s wish for children has been fulﬁlled
or abandoned.
Surgical treatment
Statements
r Surgical treatment for endometrial carcinoma should include
removal of a cytological sample from the abdominal cavity,
hysterectomy, bilateral adnexectomy and pelvic and para-aortic
lymphadenectomy up to the renal pedicle
r In the presence of serous or clear cell carcinoma, multiple
peritoneal biopsies should be taken and omentectomy should be
carried out
r In stages pT1a, pT1b and in the presence of G1 or G2,
lymphadenectomy is optional
r In stage pT2b, the parametria should also be resected
r In advanced stages, resection of the tumor should be as complete as
possible, in order to improve the effectiveness of adjuvant systemic
and radiotherapeutic measures
If a lymphadenectomy has not been performed since
stage 1a or 1b and G1 or G2 had been suspected but the
ﬁnal histology shows a higher stage or grade or high risk
histology, the surgical staging should be completed in a
second operation, if possible.
Similarly, if a simple hysterectomy has been performed
as no EC was suspected, and the pathologist describes an
unexpected EC, an adequate surgical staging should be
performed in a second operation.
Lymph node removal should not be carried out as a
sampling procedure, but deﬁnitely as systematic lym-
phadenectomy, including both, the pelvic and para-aortic
nodes up to the renal veins. At least 15 pelvic and 10 para-
aortic nodes should be removed.
If there is relevant comorbidity, lymphadenectomy may
be omitted. Lack of experience on part of the surgeon with
lymphadenectomy in obese patients, or a lack of infra-
structure for caring for patients with multiple morbidities
cannot be used to justify failure to carry out lymphade-
nectomy. In these cases, the patient should be referred to a
center for gynecological oncology.
Routine frozen-section evaluation of the hysterectomy
specimen or pelvic lymph nodes is not recommended
generally, as this method is not sufﬁciently reliable, and
complete pelvic and para-aortic lymphadenectomy is
optional in patients who are at low risk. Frozen-section
evaluation, however, may be useful in relation to speciﬁc
issues in individual patients.
If carried out by a surgeon familiar with the technique,
laparoscopic lymphadenectomy in combination with lapa-
roscopy-assisted vaginal hysterectomy/bilateral salpingo-
oophorectomy appears to be as safe as the open abdominal
procedures.
Radiotherapy
Statements
r Primary radiotherapy for endometrial carcinoma is indicated if the
patient is not operable due to comorbidity
r In patients with a high risk of local recurrence, adjuvant
radiotherapy should be carried out in order to reduce the risk of
locoregional recurrence
r Adjuvant radiotherapy has no effect on the overall survival in
stages I and II
r There are no adequate data on this topic for more advanced stages
Recent randomized controlled trials and respective
metaanalyses have shown that teletherapy of the pelvis
signiﬁcantly reduces the loco-regional recurrence rate in
stages I and II EC, but has no beneﬁcial effect on overall
survival. The effects of brachytherapy and teletherapy
reducing locoregional recurrence in stage I are comparable.
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onstrated a pN0 status in type I EC stages I and II,
teletherapy is not indicated.
Systemic therapy
Adjuvant systemic therapy
Statements
r Adjuvant endocrine therapy with gestagens has no therapeutic
effect
r In optimally operated endometrial carcinoma in stages III and IV,
chemotherapy is an alternative to radiotherapy
r In endometrial carcinomas in stages IC G3, II G3, and III, adjuvant
chemotherapy may represent an alternative to radiotherapy
A few randomized controlled trials have demonstrated
that adjuvant systemic chemotherapy might be superior to
or equivalent with traditional radiotherapy in high risk EC
or advanced EC. As the data are not sufﬁcient to recom-
mend a replacement of adjuvant radiotherapy by adjuvant
chemotherapy, the latter is classiﬁed as possible alternative
to radiotherapies in the above mentioned situations.
Palliative systemic therapy
Statements
r If surgery and/or radiotherapy are no longer possible in patients
with recurrences or metastases, gestagen treatment is recommended
for patients with progesterone receptor-positive carcinomas and
asymptomatic metastases
r If progression occurs during endocrine therapy, in receptor-
negative tumors, and when there are symptomatic and life-
threatening tumor signs, palliative chemotherapy may be useful
r The indication for systemic combination chemotherapy regimens
needs to be established strictly, in view of their lack of effect or
only marginal effect on the overall survival
Recurrences, metastases
Statements
r Resectable recurrences of endometrial carcinoma should be treated
surgically
r In inoperable patients, radiotherapy should be carried out
r If neither surgery nor radiotherapy is possible, palliative systemic
therapy should be carried out
Supportive therapy
Statement
r Supportive therapy in accordance with the guidelines is required for
prophylaxis against and minimization of treatment-related or
tumor-related symptoms
Apart from general supportive measures (antiemetic
treatment, prevention and treatment of granulocytopenia,
anemia, etc.) special consideration must be given in EC
patients to local side effects (enteritis, proctitis, cystitis,
lymphedema, vaginal dryness, vaginal stenosis and dis-
turbed sexual function).
Psycho-oncology
Statements
r Psycho-oncological care for patients with endometrial carcinoma is
an integral component of oncological diagnosis, treatment,
rehabilitation and follow-up and represents an interdisciplinary task
r The patients should be informed at an early stage about the
availability of inpatient and outpatient psycho-oncological
assistance and should receive skilled psycho-oncological care if
needed
r The patient’s quality of life must be regularly assessed during
treatment, rehabilitation, and follow-up, also in order to assess the
potential need for psycho-oncological treatment
Rehabilitation
Statement
r All patients should be informed and advised in detail by the
attending physician regarding the statutory facilities for subsequent
treatment, regular therapy, and outpatient rehabilitation
Follow-up care
Statements
r Aspects requiring attention during the follow-up include: genital
atrophy phenomena (dyspareunia), lymphedema in the lower
extremities, radiogenic reactions in the ureter, bladder and bowel,
and hormonal deﬁciencies
r Since a curative approach is possible if a local recurrence is
recognized at an early stage, a 3-month follow-up interval should
be observed in the ﬁrst 2–3 years after primary therapy, with
speculum examination, vaginal and rectal examination, and
ultrasonography if appropriate
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Statements
r More detailed imaging diagnosis is only required in symptomatic
patients
r The following points should be addressed in discussion with the
patient during the follow-up:
(1) Transient and long-term effects of the disease and treatment
(2) Assistance available (self-help groups, psychosocial cancer
counseling services)
(3) Psycho-oncological/psychotherapeutic treatment facilities
(4) Sexuality and relationship
(5) Quality of life
EC is a very common cancer. Nevertheless evidence
regarding optimal diagnosis and treatment of this disease is
rather poor as compared to other cancers. High quality
clinical trials with sufﬁcient numbers of participants are
necessary to deﬁne the optimal modalities.
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